Olorinab - Arena Pharmaceuticals

Alternative Names: APD-371

Latest Information Update: 15 Nov 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Arena Pharmaceuticals
Class Analgesics; Pyrazoles; Small molecules
Mechanism of Action Cannabinoid receptor CB2 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Pain

Most Recent Events

07 Nov 2018 Arena Pharmaceuticals plans a phase IIb trial for Pain (gastrointestinal pain)
24 Sep 2018 Adverse effects and efficacy data from a phase IIa trial in Pain released by Arena Pharmaceuticals
12 Sep 2018 Pharmacodynamics data from a preclinical trial in Pain presented at the 17^th World Congress on Pain (WCP-2018)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight